Page last updated: 2024-09-04

mdl 100240 and atrial natriuretic factor

mdl 100240 has been researched along with atrial natriuretic factor in 4 studies

Compound Research Comparison

Studies (mdl 100240)	Trials (mdl 100240)	Recent Studies (post-2010) (mdl 100240)	Studies (atrial natriuretic factor)	Trials (atrial natriuretic factor)	Recent Studies (post-2010) (atrial natriuretic factor)
21	9	0	15,455	1,105	1,760

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, B; Beach, DC; Dage, RC; Flynn, GA; French, JF; Giroux, EL; Koehl, JR; Mehdi, S	1
Bennett, T; Brunner-Ferber, F; Gardiner, SM; Kemp, PA	1
Biollaz, J; Brunner, HR; Brunner-Ferber, F; Buclin, T; Décosterd, LA; La Roche, SD; Nussberger, J; Rousso, P	1
Belloni, AS; Guidolin, D; Nussdorfer, GG; Pessina, AC; Rossi, GP; Seccia, TM; Sticchi, D	1

Trials

1 trial(s) available for mdl 100240 and atrial natriuretic factor

Article	Year
Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers. Journal of hypertension, 1999, Volume: 17, Issue:3 Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Endocrine System; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney; Male; Neprilysin; Peptidyl-Dipeptidase A; Posture; Pyridines; Reference Values; Renal Plasma Flow, Effective; Safety; Stereoisomerism	1999

Article

Year

Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.

Journal of hypertension, 1999, Volume: 17, Issue:3

Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Endocrine System; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney; Male; Neprilysin; Peptidyl-Dipeptidase A; Posture; Pyridines; Reference Values; Renal Plasma Flow, Effective; Safety; Stereoisomerism

1999

Other Studies

3 other study(ies) available for mdl 100240 and atrial natriuretic factor

Article	Year
Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. The Journal of pharmacology and experimental therapeutics, 1994, Volume: 268, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Benzazepines; Bradykinin; Male; Molecular Structure; Neprilysin; Peptidyl-Dipeptidase A; Prodrugs; Pyridines; Rats; Rats, Sprague-Dawley	1994
Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats. British journal of pharmacology, 1997, Volume: 122, Issue:8 Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Benzazepines; Bradykinin; Endothelin-1; Hemodynamics; Male; Neprilysin; Protease Inhibitors; Pyridines; Rats	1997
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. Journal of hypertension, 2006, Volume: 24, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Benzazepines; Creatinine; Fibrosis; Hypertension; Kidney; Male; Neprilysin; Pyridines; Ramipril; Rats; Receptor, Bradykinin B2	2006